SUBMISSION INFORMATION
| TIMELINE FOR ABSTRACT SUBMISSION | ||
|---|---|---|
| Registration Type | Regular Registration | |
| Date : 31 May 2025 | Abstract submission deadline | |
| Date : 1 June - 31 August 2025 | Abstract review and revision period | |
| Date : 31 August 2025 | Abstract acceptance confirmed via email | |
| Date : 31 October 2025 | Deadline for submitting oral presentation files and poster files | |
SUBMISSION GUIDELINES FORMATTING
All abstracts must be submitted by 31 May 2025, 11:59pm (GMT+7).
The submission deadline may be extended; please check the conference website for updates.
Research topics The 4th JoPPP-Thailand 2025 invites research abstracts in pharmacy and medicinal sciences. Abstracts will be accepted for oral and poster presentations under the following six topics:
- Healthcare/Pharmaceutical Policy
- Pharmaceutical Regulatory and Enforcement
- Pharmacy Practice
- Clinical Pharmacy
- Pharmaceutical Sciences
- Medical Sciences
Abstract submission guideline
- Word Count: Abstracts must be between 250 and 350 words. (A maximum word count allowance of +/- 10 words is permitted to account for discrepancies in word count tools.)
- Language: Abstracts can be written in British or American English.
- Proofreading: Authors are responsible for proofreading and ensuring the grammar and readability of the abstract before submission.
- Structure: Submit a structured abstract with the following sections: Objectives, Methods, Results and Discussion, and Conclusion.
- Submission Format:
- Abstracts must be submitted via the official abstract submission system.
- Authors may prepare the abstract in a Word document and then copy and paste it into the designated space within the submission system.
- Formatting
- Use both uppercase and lowercase characters as appropriate.
- Avoid using all uppercase letters.
- Content Limitations: Figures, tables, and references are not permitted in the abstract.
- Acknowledgment of Submission:
- Upon submission, the system will generate an acknowledgment email sent to the presenting author’s email address.
- Ensure you receive the confirmation email (check your spam/junk folder if necessary).
- If no acknowledgment is received, immediately contact the conference organizers at [email protected].
- Notification of Decision: The Conference Scientific Chair will notify authors of acceptance or rejection via email by 31 August 2025.
- Inquiries: For any questions regarding abstract submission, contact [email protected].
- Registration Requirement: The presenting author of an accepted abstract must register and pay the conference fee by the specified deadlines. Failure to complete registration by the deadline will result in the abstract being withdrawn from the final program.
Presentation modes
Please indicate the mode of presentation that you intended during submission.
Oral presentation
- Presentation Format:
Authors presenting their work orally will have 10 minutes to deliver their presentation, followed by a 5-minute Q&A session. - Session Structure:
Oral presentations will be conducted in three parallel sessions:- Policy and Regulation:
- Abstracts submitted under Healthcare/Pharmaceutical Policy and Pharmaceutical Regulation and Enforcement will be assigned to this session.
- Clinical and Pharmacy Practice:
- Abstracts submitted under Pharmacy Practice and Clinical Pharmacy will be assigned to this session.
- Health and Medical Sciences:
- Abstracts submitted under Pharmaceutical Sciences and Medical Sciences will be assigned to this session.
- Policy and Regulation:
-
Session Facilitation:
Each session will be facilitated by a chair and a co-chair. - Evaluation:
- Presentations will be evaluated by the session’s chairs and co-chairs.
- The evaluation scores will contribute to the total score, which will be used to determine the best oral presentations.
- Absence from the oral presentation will result in ineligibility for the Best Oral Presentation Award.
Poster presentation
- Presentation Format:
Authors presenting in the poster exhibition are allocated 5 minutes to present their work, followed by a 3-minute Q&A session. - Session Structure:
Poster presentations will be conducted in three parallel sessions:- Policy and Regulation:
- Abstracts submitted under Healthcare/Pharmaceutical Policy and Pharmaceutical Regulation and Enforcement will be assigned to this session.
- Clinical and Pharmacy Practice:
- Abstracts submitted under Pharmacy Practice and Clinical Pharmacy will be assigned to this session.
- Health and Medical Sciences:
- Abstracts submitted under Pharmaceutical Sciences and Medical Sciences will be assigned to this session.
- Policy and Regulation:
-
Session Facilitation:
Each session will be facilitated by scientific committees. - Evaluation and Eligibility:
- Presentations will be evaluated by scientific committees.
- The presenting author must be present at the poster during their assigned time. Absence from presenting the poster will result in ineligibility for the Best Poster Award.
- The evaluation score of the presentation will contribute to the overall criteria for selecting the Best Poster Award.
Abstract Publication
- Publication Venue:
Accepted abstracts will be published in the Journal of Pharmaceutical Policy and Practice (JoPPP), a leading pharmacy journal with a 2023 CiteScore of 4.7 and an Impact Factor of 3.3 (2023). JoPPP is published by Taylor & Francis. For more information, visit: https://www.tandfonline.com/journals/jppp20. - Consent for Publication:
The presenting author will be required to provide consent for publication in JoPPP upon confirmation of abstract acceptance. -
Publication Policy:
- Each presenting author who successfully registers and pays the conference fee is eligible to publish ONLY ONE abstract in the journal.
- Presenting authors submitting multiple abstracts must choose ONE abstract for publication.
- Authors who wish to publish additional abstracts will incur an extra charge of 50 USD per abstract.
Poster And Slide Preparation Guideline
Slide preparation
- File Format: Presentations should be prepared in either PPT or PDF format. Please ensure the file is compatible with standard presentation software.
- Slide Limit: For a 10-minute talk, we recommend a maximum of 20 slides to maintain clarity and time management.
- Submission Deadline: All presentation files must be submitted to the shared folder link (to be provided shortly) by 31 October 2025, 24:00 (GMT+7). The Scientific Committee will organize and prepare your presentation files in advance, ensuring they are ready in your designated room for a smooth presentation
Poster preparation
- Poster Dimensions
Size: Standard size of A0 (84.1 cm x 118.9 cm) (Portrait orientation). - Content Requirements
- Title: Include the title of your presentation at the top of the poster. Use large, bold fonts for visibility.
- Author(s) and Affiliation(s): Clearly list the name(s) of the author(s) and their respective institution(s) directly beneath the title.
- Sections: Organize the content into clear sections, such as: Introduction or Background, Objectives, Methods, Results, Conclusion or Discussion. Include key references in a smaller font at the bottom of the poster, if applicable. Acknowledge funding sources or collaborators, if relevant.
- Design Recommendations
- Font Size: Use a minimum of 24-point font for text to ensure readability from a distance.
- Font Style: Use clear, professional fonts (e.g., Arial, Calibri, or Times New Roman). Avoid decorative fonts.
- Graphics: Include high-quality graphs, charts, and images to support your data. Ensure all visuals are labeled and have descriptive captions.
- Color Scheme: Use a professional and visually appealing color scheme. Avoid using overly bright or clashing colors.
- Spacing: Leave enough white space to make the poster easy to read and not overly cluttered.
- Printing and Setup
Participants can choose to:
- Print the poster themselves and bring it to the conference.
- Order a printing service through the organizing committee and collect the printed poster at the registration desk on the conference dates. Participants opting for the printing service must:
- Prepare their poster as a PDF file to ensure accurate formatting.
- Submit the poster file to the shared folder link (to be provided later) by 31 October 2025, 24:00 (GMT+7).
- Details regarding material options, prices, and payment methods will be provided at a later date.
Awards
Best Oral presentation wards
1.Policy and regulation
2.Clinical and pharmacy practice
3.Health and medical sciences
Best Poster presentation wards
1.Policy and regulation
2.Clinical and pharmacy practice
3.Health and medical sciences
Abstract Evaluation Rubrics
Rationale (Clarity and Significance of Purpose)
5: The rationale is exceptionally clear, compelling, and addresses a highly significant problem or question.
4: The rationale is clear and addresses an important problem or question.
3: The rationale is somewhat clear but lacks full articulation of significance.
2: The rationale is unclear or addresses a minor problem or question.
1: The rationale is poorly stated, irrelevant, or absent.
Methodologies (Appropriateness and Detail)
5: Methodology is exceptionally well-detailed, appropriate, and rigorous for the research question.
4: Methodology is clearly explained, appropriate, and generally rigorous.
3: Methodology is moderately clear and appropriate but lacks detail or rigor.
2: Methodology is vague or not entirely appropriate for the research question.
1: Methodology is poorly described, inappropriate, or absent.
Accuracy of Data Analysis
5: Data analysis is accurate, thorough, and well-matched to the research question. Results are clearly presented and meaningful.
4: Data analysis is accurate and relevant but could benefit from additional detail or clarity.
3: Data analysis is mostly accurate but may contain minor errors or inconsistencies.
2: Data analysis contains significant errors, inconsistencies, or lack of clarity.
1: Data analysis is absent, incorrect, or inappropriate for the research.
Implications (Relevance to Pharmaceutical Policy and Practice)
5: Implications are exceptionally well-articulated, demonstrating clear and significant relevance to advancing pharmaceutical policy and practice.
4: Implications are clearly stated and provide meaningful contributions to pharmaceutical policy and practice.
3: Implications are somewhat clear and relevant but lack depth or strong connections to pharmaceutical policy and practice.
2: Implications are unclear, have limited relevance, or are weakly connected to pharmaceutical policy and practice.
1: Implications are irrelevant, insignificant, or fail to address pharmaceutical policy and practice.
Novelty (Originality and Innovation)
5: The abstract demonstrates exceptional originality and introduces innovative ideas or approaches.
4: The abstract is original and includes some innovative aspects.
3: The abstract is moderately original but lacks significant innovation.
2: The abstract has limited originality or relies heavily on previously established ideas.
1: The abstract lacks originality and does not present any new ideas or perspectives.